Recruiting PHASE4 INTERVENTIONAL 2-arm NCT04286399

Asian Diabetes Outcomes Prevention Trial (ADOPT)

Sponsor: Mackay Memorial Hospital

Conditions Cardiovascular Diseases Diabetes Mellitus

Interventions Beta blocker Renin-angiotensin-aldosterone system inhibitors SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product

Updated 5 times since 2020 Last updated: Apr 28, 2021 Started: Jul 1, 2019 Primary completion: Jun 30, 2022 Completion: Jun 30, 2034

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04286399, this PHASE4 trial focuses on Cardiovascular Diseases and Diabetes Mellitus and remains actively recruiting participants. Sponsored by Mackay Memorial Hospital, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
May 2021 — Jul 2024 [monthly]

Recruiting PHASE4
Jan 2021 — May 2021 [monthly]

Recruiting PHASE4
Mar 2020 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mackay Memorial Hospital
Medanta, The Medicity, India
National Heart Centre Singapore
National Taiwan University Hospital
Peking University People's Hospital
Public Health Foundation of India
Putrajaya Hospital, Malaysia
Singapore General Hospital
Universiti Teknologi Mara

Data source: National Heart Centre Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore